Furthermore, clinical trials with SMO inhibitors so far have failed to prove a clear therapeutic benefit for patients with non-BCC malignancies including colorectal, ovarian and pancreatic cancer [13, 14]. Here, SMO is linked to pancreatic neoplasm.